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Background: Growing evidence indicates that endometriosis is an epigenetic disease. Encouragingly, histone
deacetylases (HDACs) and DNA methyltransferases have been shown to be promising targets by numerous
in vitro studies. However, only a few studies have shown promising effects of HDAC inhibition in preclinical
studies in endometriosis. While lysine-specific demethylase 1 (LSD1) is recently found to be aberrantly expressed in
endometriosis, and that the treatment of endometriotic stromal cells with tranylcypromine (TC), an LSD1 inhibitor,
significantly reduced cellular proliferation, cell cycle progression, and invasiveness, the in vivo effect of TC treatment
is currently lacking. This study sought to evaluate the effect of TC in a mouse model of endometriosis.
Methods: Forty-seven female C57BL/6 mice were used in this experimentation. All mice, except those randomly
selected to form Sham surgery (M) and specificity control (S) groups, received an endometriosis-inducing surgery.
Group S was set up mainly to ensure that the reduced generalized hyperalgesia in mice treated with TC is not
due to any possible analgesic effect of TC, but rather resulting from the treatment effect specific to endometriosis.
Two weeks after the surgery, mice that received surgery were further divided randomly into 3 groups: 1) untreated
group (U); 2) low-dose TC group (L); 3) high-dose TC group (H). Group S received the same treatment as in group H.
Two weeks after treatment, all mice were sacrificed and their ectopic endometrial tissues were harvested and analyzed
by immunohistochemistry analysis. Hotplate test was administrated to all mice before the induction, treatment and
sacrifice. Lesion size, hotplate latency, immunoreactivity against markers of proliferation, angiogenesis, H3K4
methylation, and of epithelial-mesenchymal transition (EMT).
Results: TC treatment significantly and substantially reduced the lesion size and improved generalized
hyperalgesia in a dose-dependent fashion in mice with induced endometriosis. In addition, TC treatment
resulted in reduced immunoreactivity to biomarkers of proliferation, angiogenesis, and H3K4 methylation,
leading to arrested EMT and lesion growth.
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Conclusion: In light of our previously reported reduced cellular proliferation, cell cycle progression and invasiveness
resulting from the LSD1 inhibition in in vitro studies, our data strongly suggest that LSD1 is a promising therapeutic
target for endometriosis.
Trial registration: Not applicable.
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Endometriosis, characterized by the deposition and
growth of functional endometrial-like tissues outside the
uterine cavity, is an estrogen-dependent disease, affect-
ing roughly 6–10 % of women of reproductive age [1]. It
is a leading cause of disability in women of reproductive
age and a major contributing cause for dysmenorrhea,
pelvic pain and subfertility [2], impacting negatively on
their quality of life [3]. Despite extensive research, the
development of effective and safe drugs for endometri-
osis treatment has been frustratingly slow [4].
Endometriosis is, first and foremost, a hormonal
disease, characterized by the increased local produc-
tion of estrogens due to molecular aberrations in ste-
roidogenesis [5]. It is also recognized as a inflammatory
condition [6], featuring overexpression of inflammatory
genes, the release of pro-inflammatory cytokines [7, 8],
the activation of NF-κB [9–11], and the infiltration of
macrophages and lymphocytes [12–14].
Since the report, published over a decade ago, of
HOXA10 hypermethylation in eutopic endometrium
from women with endometriosis, which ventured the
view that “endometriosis may also be an epigenetic
disease” [15], accumulating evidence provides strong
support for this view [16–19]. Encouragingly, drugs
(the so-called “epi-drugs”) targeting aberrant but re-
versible epigenetic modifications, mainly DNA methy-
lation and histone deacetylation, have been shown to
be of therapeutic potential for treating endometriosis.
Specifically, histone deacetylases (HDACs) and DNA
methyltransferases (DNMTs) have been shown to be
promising targets by numerous in vitro studies [20–24].
In contrast, only a few studies have shown promising ef-
fects of HDAC inhibition in preclinical studies in endo-
metriosis [25–27].
Epigenetic regulation of gene transcription is medi-
ated by a diverse family of protein complexes, including
chromatin remodeling and transcription factors [28].
The epigenetic landscape is complex, encompassing
DNA methylation, histone code, non-coding RNA, nu-
cleosome positioning, and DNA sequence. In particular,
histone lysine methylation has recently been emerged
as one key determinant of transcriptional regulation[29]. The first protein showing histone lysine (K)
demethylase (KDM) activity identified in mammals is
lysine-specific demethylase 1 (LSD1 or KDM1A) [30].
LSD1 is a flavin-containing amino oxidase (AO) that
specifically demethylates mono- or di-methylated lysine
4 at histone H3 (H3K4me1 and H3K4me2) via a flavin ad-
enine dinucleotide (FAD)-monoamine oxidase (MAO)
mechanism [31], and, as such, can be inhibited by com-
pounds related to the MAO inhibitor (MAOI) class of
pharmaceuticals [32]. LSD1 is intimately involved in DNA
methylation [33], interact with nuclear hormone receptors
such as estrogen receptor [34], have a potential role in the
repression of E-cadherin and thus in the epithelial-
mesenchymal transition (EMT) [35] and in the regulation
of VEGF [36]. It also interacts closely with HDACs to sup-
press gene expression [30]. In endometriosis, several lines
of evidence implicate the involvement of LSD1. First, a
global H3K4 and H3K9 hypomethylation in endometriotic
lesions has been reported recently [37]. In addition, global
H3 hypoacetylation as well as HDAC1 overexpression also
have been reported [17, 38, 39]. While selective inhibition
of prostaglandin E2 receptors EP2 and EP4 is shown to
have many desirable therapeutic effects [40], it has no ef-
fect on LSD1 expression in endometriotic lesions [41].
We have recently shown that LSD1 gene and protein
expression is elevated in endometriosis, and treatment
of endometriotic stromal cells with tranylcypromine
(TC), an LSD1 inhibitor, significantly reduced cellular
proliferation, cell cycle progression, and invasiveness
[42]. However, the in vivo effect of TC treatment is cur-
rently lacking. In light of scant, if any, preclinical studies
on the use of epi-drugs other than HDAC inhibitors in
endometriosis, this study sought to evaluate the effect of
TC in a mouse model of endometriosis.
Methods
Mouse experiment
Forty-seven virgin female C57BL/6 mice, 8 weeks old
and about 18–20 g in weight, were purchased from
Shanghai BiKai Laboratory Animal Center (Shanghai,
China) and used for this study. They were housed indi-
vidually in cages, maintained under controlled condi-
tions with a light/dark cycle of 12/12 h, and had access
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this study were performed under the guidelines of the
National Research Council’s Guide for the Care and
Use of Laboratory Animals and approved by the institu-
tional experimental animals review board of Shanghai
OB/GYN Hospital, Fudan University.
After 3 days of acclimatization and before the surgery
(see Surgical procedures below), a baseline hotplate test
(Test 1) was administrated to all mice as reported pre-
viously [25]. Thereafter, all mice, except 7 and 9 that
were randomly selected to form groups M (sham surgery)
and S (for specificity control), respectively, received an
endometriosis-inducing surgery. Two weeks after the
surgery, the 31 mice that received surgery were fur-
ther divided at random into 3 groups: 1) untreated
(U) group (n = 11); 2) low-dose TC (L) group (n = 10);
3) high-dose TC (H) group (n = 10). Mice in group M
received similar care as others but received a sham
surgery (fragments of fat tissues, instead of endomet-
rial tissue fragments). The set-up of group M was
meant to validate the results obtained from humans,
and their endometrial tissue samples were subjected
to immunohistochemistry analysis of LSD1, using the
same LSD1 primary antibody used in humans. They
were sacrificed 2 weeks after surgery.
Two weeks after induction, mice in group U received
0.3 mL intra-peritoneal (i.p.) injection of sodium sulfate
solution (a solvent for TC) every two days, while mice in
groups L and H received i.p. injection of 1 or 2 mg/kgFig. 1 Schematic illustration of the experimental design of this study. S
endometriosis-induction surgery; Sham, sham surgery, a surgery that tra
fragments, to the peritoneum of the pelvic cavity and the mesenteriumbodyweight TC dissolved in 0.3 ml sodium sulfate solu-
tion every two days, respectively. Meanwhile, group S re-
ceived a high-dose TC treatment in identical fashion as
to group H. The dose in group H was about the half of
the dose used in a cancer study [43]. Group S was set up
mainly to ensure that the reduced generalized hyperalge-
sia, if any, in mice treated with TC is not due to any pos-
sible analgesic effect of TC, but rather resulting from the
treatment effect specific to endometriosis. All groups
received identical care except the administration of
different types and/or doses of drugs. The schematic
illustration of the experimental design is shown in Fig. 1.
To gauge the change in thermal latency as a result of
induced endometriosis, a second round of hotplate test
(Test 2) was administrated to all mice two weeks after
surgery and before the treatment. Two weeks after treat-
ment, the third round of hotplate test (Test 3) was ad-
ministrated to all mice. Then the mice were sacrificed
through cervical dislocation. The abdominal cavity was
immediately reopened through the original incision, and
all lesions were measured with two perpendicular diame-
ters (the length D1 and the width D2). The surface area
of each endometrial implant tissue was calculated by the
formula: S = π × D1 × D2/4 (in mm
2). The total surface
area of ectopic lesions in each mouse was evaluated. Ec-
topic lesion tissues in groups H, L and U were harvested
and fixed immediately after collection in 10 % formalin
and embedded in paraffin for histopathologic examin-
ation and immunohistochemical analysis.ome abbreviations used in the figure: Endo-induction surgery,
nsplant fragments of fat tissues, instead of endometrial tissue
of the small intestine; Sx, Surgery; TC, tranylcypromine
Sun et al. Reproductive Biology and Endocrinology  (2016) 14:17 Page 4 of 13Surgical procedures
Anaesthetized with 300 mg/kg chloral hydrate, surgery
was performed aseptically to auto-transplant small
pieces of uterine to the peritoneum of the pelvic cavity
and the mesenterium of the small intestine, as described
previously [25]. Laparotomy was performed and the left
uterine horn was removed. The excised horns were
immersed in a sterile lactate solution and opened longi-
tudinally. Each uterine segment was then cut into four
smaller, roughly equal-sized (2.5 mm in diameter) frag-
ments. A total of 4 uterine fragments were sutured to
the peritoneal wall of the lower part of the lateral ab-
dominal and pelvic cavity with a 7/0 braided silk suture.
Then the midline incision was closed with a 3/0 braided
silk suture. After surgery, all mice were administrated
with 40,000 U of penicillin i.m. to prevent infection. In
addition, they received subcutaneous injection of
0.2 mg/kg bodyweight 17β-estradiol solution twice a
week for the next 2 weeks to stimulate and maintain
the growth of endometrial implants [25]. Endometriosis
was successfully induced in all mice.
Immunohistochemistry and histochemistry
Mice ectopic lesions were fixed for 24 h at room
temperature with 10 % formalin neutral buffer solution.
After fixation, the tissues were placed in 70 % ethanol
overnight at 4 °C, then embedded in paraffin and sec-
tioned at 4-μm thickness. For each paraffin-embedded
tissue block, the first resultant slide was stained for H&E
to confirm pathologic diagnosis, and the subsequent
slides were stained for proliferating cell nuclear antigen
(PCNA) (a marker for cellular proliferation), vascular
endothelial growth factor (VEGF), CD31 (for counting
microvessel density or MVD), H3K4me1, H3K4me2,
E-cadherin and vimentin. Routine deparaffinization
and rehydration procedures were performed following
published protocols.
For antigen retrieval, the slides were heated at 98 °C in
the EDTA buffer (pH 8.0) or the citric acid solution
(pH 6.0) (depending on the primary antibody used) for a
total of 30 min and cooled naturally at room temperature.
The rabbit polyclonal antibodies against PCNA (Thermo
Littleton, CO, USA), H3K4me1 (Abcam, Cambridge, MA,
USA), H3K4me2 (Abcam), VEGF (Santa Cruz, TX, USA),
CD31 (Abcam), E-cadherin (CST, MA, USA), vimentin
(Abcam) diluted to 1:100, 1:100, 1:100, 1:50, 1:50, 1:100
and 1:200, respectively, were used as primary antibodies.
Normal control mouse endometrial tissues in group M
and the ectopic endometrial tissues in group U were also
incubated with a rabbit polyclonal antibody against LSD1
(1:100; Novus Biologicals, Littleton, CO,USA) at 4 °C
overnight. After slides were rinsed by PBS, they were
incubated at room temperature for 15 min and 10 min,
respectively, in biotinylated secondary antibody andtreptavidin-labeled HRP (MR-SPR120, Shanghai MingRui
BioTech, Shanghai, China). Finally, the sections were
stained for 2 min or until appropriate for microscopic
examination with diaminobenzidine. The sections were
then counter-stained with haematoxylin, dehydrated in a
graded alcohol series, cleared in xylene, and finally
mounted in balsam. Human invasive breast cancer tissue
samples were used as positive control. Negative control
sections were treated identically, except that the specific
antibody was replaced by the same concentration of nor-
mal rabbit serum. No positive reaction was observed
under these conditions. Since TC blocks LSD1 activity
[44], immunohistochemistry analysis of LSD1 in treated
mice was not performed.
The number and intensity of positive cells were
counted by Image Pro-Plus 6.0 (Media Cybernetics, Inc.,
Bethesda, Maryland, USA). Images were obtained with
the microscope (Olympus BX51, Olympus, Tokyo,
Japan) fitted with a digital camera (Olympus DP70,
Olympus, Tokyo, Japan). A series of 3–5 random images
on several sections were taken for each immunostained
parameter to obtain a mean value. Staining was defined
via color intensity, and a color mask was made. The
mask was then applied equally to all images, and meas-
urement readings were obtained. Immunohistochemical
parameters assessed in the area detected included (a) in-
tegrated optical density (IOD); (b) total stained area (S);
and (c) mean optical density (MOD), which is defined as
MOD = IOD/S, equivalent to the intensity of stain in all
positive cells.Statistical analysis
The comparison of distributions of continuous variables
between or among two or more groups was made using
the Wilcoxon’s and Kruskal’s test, respectively, and the
paired Wilcoxon test was used when the before-after
comparison was made for the same group of subjects.
Pearson’s or Spearman’s rank correlation coefficient was
used when evaluating correlations between two variables
when both variables were continuous or when at least
one variable was ordinal. To see whether TC treatment
and other possible factors were responsible for the
change in hotplate latency before and after the treat-
ment, a multiple linear regression model was used. The
treatment of 0, 1 mg/kg, and 2 mg/kg TC was coded as
0, 1, and 2, respectively.
To further characterize the treatment effect, we car-
ried out a hierarchical cluster analysis with scaled data
and the Euclidean distance as the similarity metric, with
the average linkage being the clustering method. The
resulting dendrogram was represented as a heatmap. A
multidimensional scaling (MDS) analysis was performed
to discriminate all mice used in this study.
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significant. All computations were made with R 3.2.2
[45] (www.r-project.org).
Results
Before the treatment was started, two mice in group
L died at the 7th day after surgery following the 17β-
estradiol injection, and 2 mice each in groups S and
H were found dead at the 5th day after the treatment
was started. An autopsy ensued for all dead mice, but
no apparent abscess, hemorrhage, obstruction, or em-
bolus was found. The respiratory, circulation, and
urinary systems, and the liver and spleen all appeared
normal. Since mice in groups H and S all received
higher TC dosage, it is likely that the toxicity might
have resulted in the demise. Consequently, groups M,
U, L, H and S had 7, 11, 8, 8 and 7 mice, respectively
at the end of the experiment and were used in the
following analyses. In the L group, TC appeared to be
well tolerated, and no adverse event was observed.Fig. 2 a Representative photo micrographs showing immunoreactivity to L
and from a mouse that had induced endometriosis but received no treatm
of LSD1 staining levels in normal endometrium from mice in group SHAM
p-value of the difference between the two groups is less than 0.001Inhibition of LSD1 results in reduced lesion size and
improved hyperalgesia in mice with induced endometriosis
We first show that, compared with the control endomet-
rium from mice that received sham surgery (and thus
had no endometriosis), the LSD1 staining levels in endo-
metriotic lesions in group U mice were significantly ele-
vated (p = 4.4 × 10−4; Fig. 2), similar to what we found in
humans [42].
We also found that TC treatment dose-dependently re-
duced the lesion size (Fig. 3a; p = 1.8 × 10−7, R2 = 0.67, by a
multiple linear regression analysis with log-transformed
lesion size). In fact, low- and high-dose TC treatment
resulted in an average of 62.4 and 76.7 % reduction
in lesion size, respectively (p = 0.0013 and p = 0.0003,
respectively; Fig. 3a).
As expected, there was no difference in hotplate la-
tency prior to the induction of endometriosis (p = 0.16;
Fig. 2b). However, 2 weeks after the induction but before
the TC treatment, a significant difference in hotplate la-
tency among the 5 groups of mice was found (p = 0.0001;SD1 in the endometrium from a mouse that received a sham surgery
ent. Magnification: X400. The scale bar represents 125 μm. b Boxplot
and in ectopic endometrium from mice in group U. “***” denotes the
Fig. 3 a Boxplot of lesion size in different treatment groups. “***” denotes the p-values of the difference between the designated group and the
untreated group are less than 0.001. b The time-course of the mean hotplate latency in different treatment groups. Abbreviations used in the
figure: M, sham surgery group; U, untreated mice; L, mice treated with low-dose TC; H, mice treated with high-dose TC; S, specificity control group
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significantly decreased latency as compared with those
without (p = 2.1 × 10−6; Fig. 3b), consistent with what
we reported previously [25–27]. Two weeks after
treatment, there was a significant difference in hot-
plate latency among the 4 groups of mice (p = 0.0003;
Fig. 3b; Hotplate latency in the sham group was not
measured). In fact, mice with endometriosis that re-
ceived TC treatment had significantly longer laten-
cy—in a dose-dependent manner—than those without
(p = 0.0003, by multiple linear regression controlling
for before-treatment levels and the bodyweight at sac-
rifice, R2 = 0.87; Fig. 3b). This can be seen from the
improved latency in mice with endometriosis and
treated with TC but not in untreated mice (Fig. 3b).
The mice in group S, on the hand, had no significant
change in latency (p = 0.40; Fig. 3b), suggesting that
the improvement in hotplate latency in TC-treated
mice was endometriosis-specific.
Inhibition of LSD1 results in reduced proliferation and
angiogenesis in ectopic endometrium
We further performed an immunohistochemistry ana-
lysis of PNCA, VEGF, CD31, H3K4me1, H3K4me2, E-
cadherin, and vimentin for ectopic endometrium. We
found that PCNA, H3K4me1 and H3K4me2 staining
was seen in cellular nuclei in both the stromal andepithelial cells of the ectopic endometrium, while VEGF
immunoreactivity was seen mostly in the cytoplasm of
glandular epithelial cells as well as of vascular endothe-
lial cells (Fig. 4). As expected, CD31 staining was seen
mostly in vascular endothelial cells, and E-cadherin
staining was seen mostly in cell membranes of glandular
epithelium. On the other hand, vimentin staining was
seen in the cytoplasm of stromal cells (Fig. 4).
We found that the TC dosage correlated closely with
the immunoreactivity to all these proteins. In particular,
the TC dosage correlated negatively with staining of
PCNA (r = −0.87, p = 2.7 × 10−9; Spearman’s correlation),
VEGF (r = −0.75, p = 7.9 × 10−6), MVD (CD31) (r = −0.80,
p = 4.3 × 10−7), and vimentin (r = −0.52, p = 0.0054), but
positively with that of E-cadherin (r = 0.55, p = 0.0029),
H3K4me1 (r = 0.64, p = 0.0004), and H3K4me2 (r = 0.63,
p = 0.0005). For all markers, there was a significant
difference in immunoreactivity among the 3 groups
(all p-values < 0.015; Fig. 5a, c-h). Precisely as ex-
pected, TC treatment resulted in elevated H3K4me1
and H3K4me2 staining levels (Fig. 5g, h). Linear regres-
sion analyses indicated that TC dosage was negatively as-
sociated with the decrease in immunoreactivity to PCNA
(p = 2.8 × 10−7, R2 = 0.76; square-root transformed to im-
prove normality; Fig. 5a), VEGF (p = 5.2 × 10−6, R2 = 0.57;
Fig. 5c), MVD (p = 1.5 × 10−6, R2 = 0.61; Fig. 5d), and
vimentin (p = 0.0026, R2 = 0.31; Fig. 5f) but positively
Fig. 4 Representative micrographs showing immunoreactivity to PCNA, VEGF, CD31 (MVD), E-cadherin, vimentin, H3K4me1, and H3K4me2,
in ectopic endometrium among different groups. The abbreviations used: Low-TC, tissue sample taken from a mouse treated with low-dose
TC; High-TC, treated with high-dose TC; UT, untreated. Magnification in all figures: X400. The scale bar represents 125 μm
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Fig. 5 a Boxplot of PCNA staining levels in different groups of mice. b Scatter plot of lesion size vs. the PCNA staining levels in ectopic endometrium.
The dashed line represents the regression line. Each alphabet represents one data point, where U, L, and H denote that the mouse was
from group UT, L, and H, respectively. The numbers in the figures are p-values for statistical significance in testing the difference among
different groups (Kruskal-Wallis test). c Boxplot of VEGF staining levels in different groups of mice. d Boxplot of the number of CD31-positive
microvessels in different groups of mice. e Boxplot of E-cadherin staining levels in different groups of mice. f Boxplot of vimentin staining levels in
different groups of mice. g Boxplot of H3K4me1 staining levels in different groups of mice. h Boxplot of H3K4me2 staining levels in different groups of
mice. ‘*’, p < 0.05; ‘**’, p < 0.01; ‘***’, p < 0.001. denoting the statistical significance levels as compared with the untreated group
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(p = 0.0024, R2 = 0.31; Fig. 5e), H3K4me1 (p = 0.0005, R2 =
0.39; Fig. 3g), and H3K4me2 (p = 0.0004, R2 = 0.39; Fig. 5h).
As expected, the lesion size correlated positively
with the PCNA staining levels (r = 0.87, p = 3.5 × 10−9,
both square-root transformed; Fig. 5b). The PCNA
immunoreactivity correlated positively with the MVD
(r = 0.64, p = 0.0003), which, in turn, positively corre-
lated with that of VEGF (r = 0.67, p = 0.0001). The
VEGF staining levels correlated negatively with that
of both H3K4me1 (r = −0.42, p = 0.029) and H3K4me2
(r = −0.49, p = 0.0089).Hierarchical cluster analysis of measured phenotypes and
IHC immunoreactivity
To gain more insights into the possible mechanisms of
TC treatment effect, we performed a hierarchical cluster
analysis of all measured phenotypes and IHC immunore-
activity measurements, all square-root transformed, and
the results are presented as a heatmap (Fig. 6). We can
see from Fig. 6 that all mice could be grouped roughly
into 2 clusters: cluster 1 is featured by a high growth
propensity, namely, larger lesion size, and elevated im-
munoreactivity to VEGF, PCNA, vimentin and higher
MVD in the ectopic endometrium. In addition, it is
Fig. 6 Hierarchical clustering heatmap of phenotypes/immunoreactivity measurements and mice. The heatmap was organized by clustering both
mice (by rows) and measured phenotypes/immunoreacivity measurements (by columns). The red color represents the minimal values while the
white color represents the maximal values. The alphabets on the rightmost panel represents which treatment group the mouse came from,
where the group abbreviations are the same as in Fig. 5. The labels in the bottom are the names of the phenotypes/immunoreactivity measurements.
HPL: hotplate latency. The color strip on the left: The violet color indicates mouse from the untreated group, the blue color, the low-dose TC group,
and the dark blue color, the high-dose TC group
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noreactivity to H3K4me1/me2 and E-cadherin. This
cluster includes exclusively all mice in the untreated
group. Cluster 2 is the opposite, and is characterized by
a reduced growth propensity and longer latency, heavier
bodyweight and elevated H3K4me1/me2 and E-cadherin
staining. This cluster includes exclusively all mice thatreceived TC treatment, although mice in the low- and
high-dosage groups appeared to overlap (Fig. 6).
From the heatmap, it seems that those proteins in-
volved in growth propensity can be clustered together,
which forms a greater cluster with the lesion size
(Fig. 6). In contrast, hotplate latency, E-cadherin and
H3K4me1/me2 staining levels formed another group
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and MVD scores to carry out a multidimensional
scaling analysis. The result is shown in Fig. 7. We
can see that, indeed, the use of these measurements
can cluster the mice very nicely, almost a perfect
match with the original treatment assignment (Fig. 7).
Discussion
In this study, we have demonstrated that TC treat-
ment significantly and substantially reduced the lesion
size and improved generalized hyperalgesia in a dose-
dependent fashion in mice with induced endometriosis. In
addition, TC treatment results in reduced immunoreactiv-
ity to VEGF, PCNA, and vimentin but elevated E-cadherin
and H3K4me1/me2 staining levels, leading to arrested
EMT and decreased MVD as well as lesion growth. This,
in conjunction with our previously reported reduced cel-
lular proliferation, cell cycle progression and invasiveness
resulting from the LSD1 inhibition in vitro studies [42],
strongly suggests that LSD1 is a promising therapeutic tar-
get for endometriosis.
Endometriotic epithelial cells are known to have in-
creased invasive propensity [46, 47], which is charac-
terized with decreased E-cadherin expression [47],
likely due to its promote hypermethylation [48]. The
loss of E-cadherin expression is a hallmark of EMT, a
highly conserved cellular process that allows polarized
and generally immotile epithelial cells to convert toFig. 7 Results of multidimensional scaling analysis using all immunoreactiv
same as used in Fig. 2bmotile mesenchymal cells, and occurs in embryonic devel-
opment, cancer, and as a physiological response to injury
[49]. EMT endows cells with migratory and invasive cap-
abilities, increasing the invasive propensity.
EMT is now well-documented in endometriosis
[50–53], featuring decreased E-cadherin expression
but increased vimentin expression in the epithelial
component of endometriotic lesions. Several tran-
scription factors known to play critical roles in EMT,
such as Snail, Twist and ZEB1 [49], are also reported
to be upregulated in endometriosis [52]. Yet Snail
uses its SNAG domain as a molecular hook to associ-
ate the LSD1/HDAC complex [54]. Once recruited to
the E-cadherin promoter, the complex may modify
histones to generate a repressive chromatin environ-
ment featuring H3K4 hypomethylation and H3/H4
hypoacetylation [55]. Our data appear to be consistent
with published data of H3, but not H4, hypoacetyla-
tion [38] and global H3K4 hypomethylation [37] and
the increased LSD1 expression [42] in endometriosis.
Our data are also consistent with the abrogated
EMT as a result of LSD1 inhibition through TC treatment,
as seen by reduced vimentin staining but increased E-
cadherin staining in the epithelial component of lesions as
well as increased H3K4me1 and H3K4me2 staining levels
in endometriotic lesions. The increased expression of E-
cadherin, a marker of epithelial cells, and the decreased
expression of vimentin, a marker of mesenchymal cells,ity data. All mice were represented by their group labels, which are the
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that LSD1 is essential for Snai1-mediated transcrip-
tional repression and for maintenance of the silenced
state of Snai1 target genes, including E-cadherin, in in-
vasive cancer cells [35], and that chromatin reprogram-
ming during EMT is LSD1-dependent [56]. Inhibition
by TC also is found to suppress Slug-LSD1 interaction,
blocking cancer cell motility and invasion [57]. Since
loss of E-cadherin is intimately related with EMT and
invasiveness, even in endometriosis [48, 51], these results
appear to give more credence to the reduced invasiveness
of endometriotic stromal cells treated with TC (Fig. 5).
The elevated LSD1 staining levels in ectopic implants
as compared with normal endometrium are also consist-
ent with our human data [42]. The reduced VEGF ex-
pression is consistent with the report that functional
deletion of LSD1 impairs VEGF transcription [36], and
also is consistent with the reduced MVD, and subse-
quently PCNA staining levels and lesion size.
Our data demonstrate a potent therapeutic effect of
LSD1 inhibition by TC, as evidenced by close to 2/3 re-
duction in lesion size in low-dose group and over 3/4 of
reduction in high-dose group. Aside from the abrogation
of the EMT process and thus invasiveness in the devel-
opment of endometriosis, the decreased angiogenesis
and cellular proliferation, LSD1 suppression by TC may
also have other desirable therapeutic effects, yet to be
identified, since the H3K4 and H3K9 demethylation is
likely to be global. For example, as a nonselective and ir-
reversible MAO inhibitor, TC is anti-depressant and
anxiolytic (used only in Germany). After all, women with
endometriosis, especially those with dysmenorrhea and
infertility, may experience anxiety [58]. It is also possible
that its use, in combination with other therapeutics such
as HDAC inhibitors, may generate synergistic thera-
peutic effect as in acute myeloid leukemia [59].
Given the cross-talks between LSD1 and HDACs
[30, 60], it is not surprising to see that the use of
LSD1 inhibitors may sensitize cancer cells to HDAC
inhibitors [61]. HDAC inhibition also has been shown
to stimulate H3K4 methylation through suppression
of KDMs including LSD1 [62]. This, in conjunction
with the data presented here and elsewhere, suggests
that LSD1 is promising candidate for targeted therapy
to treat endometriosis.
However, caution also should be exercised. Endometri-
osis is largely a benign disease and certainly is not life-
threatening. As such, it places higher premium on drug
safety as compared with other life-threatening diseases
such as cancer. While LSD1 suppression by TC may
hold promises in treating endometriosis, the high mor-
tality in mice that received high-dose of TC raises a red
flag. It is also conceivable that H3K4 demethylation may
be part of the normal physiology, and, as such, TCtreatment may have off-target toxicity. Whether TC
should be used in treating human endometriosis, dosage,
formulation, and route of delivery surely will need more
investigation and a thorough evaluation of the benefit
versus risk ratio. The encouraging results shown in this
study merely demonstrate the possibility of targeting
LSD1 for therapeutic purpose. They are not meant to
advocate TC per se for the treatment of human endo-
metriosis. Encouragingly, several LSD1 inhibitors are on
the horizon [63].
Conclusions
In summary, we found that tranylcypromine treat-
ment results in marked changes that are consistent
with retarded EMT, decreased angiogenesis and lesion
growth, and improved hyperalgesia in mice with induced
endometriosis, along with increased H3K4 methylation.
Taken together, these results suggest that LSD1 may be a
promising therapeutic target for endometriosis.
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